Toxicology & Drug Testing Billing Services To Recover Every Dollar You've Earned

Most toxicology and drug testing labs lose 20-25% of collectible revenue annually; not from low specimen volume, but definitive testing tier miscoding, missing medical necessity documentation, and payer-specific frequency violations that generalist billers miss entirely. TransLabs’ certified toxicology billing specialists close those gaps with a 98% clean claims rate and 30% faster A/R, with measurable growth in 90 days.
Toxicology & Drug Testing Billing Services
0%
Client Retention Rate
0%
First-Pass Claim Rate
0%
Avg. Revenue Growth
0%
Avg. Denial Reduction

Why Toxicology and Drug Testing Laboratories Lose Revenue Every Day

Toxicology billing carries a compliance burden unlike almost any lab discipline. Presumptive-versus-definitive testing, tiered G-codes, per-day limits, and medical necessity documentation aren’t rules generalists track. In pain management and substance use settings, where testing happens nearly every visit, small errors compound fast. Audits reveal years of loss, one miscoded tier at a time.

The Five Revenue Leaks Most Toxicology Labs Don't Know They Have

Definitive Testing Tier Miscoding

Missing Medical Necessity Documentation for Definitive Testing

Presumptive & Definitive Same-Day Billing Conflicts

Frequency Limitation Violations

Specimen Validity & Confirmation Bundling Errors

Toxicology & Drug Testing Billing Services

Every Toxicology and Drug Testing Discipline, Billed Correctly; From Specimen Collection to Final Payment

From point-of-care presumptive screening to definitive LC-MS/MS confirmation testing, our AAPC and AHIMA certified toxicology coders know the CPT and HCPCS coding rules, the tier selection logic, and the payer-specific medical necessity requirements for every drug testing setting, from pain management clinics to SUD treatment programs to forensic laboratories.

Presumptive (Qualitative) Drug Testing

CPT 80305--80307

Point-of-care and lab-based qualitative screening across drug classes including opioids, amphetamines, benzodiazepines, cannabinoids, cocaine metabolites, and barbiturates, reported by direct optical observation (80305), instrument chemistry analyzer (80306), or immunoassay with chromatography capability (80307).

Key Billing Consideration

Only one presumptive code may be billed per patient per day regardless of how many drug classes were screened --- billing more than one presumptive code on the same date of service is a routine, easily flagged overbilling pattern.

Definitive Drug Testing --- Medicare Tiered System

HCPCS G0480--G0483, G0659

Definitive, quantitative identification of individual drugs and metabolites by GC/MS or LC/MS, tiered strictly by the number of drug classes tested: G0480 (1-7 classes), G0481 (8-14 classes), G0482 (15-21 classes), and G0483 (22 or more classes).

Key Billing Consideration

Tier selection must match the exact number of drug classes ordered, tested, and documented in the chart --- billing a higher tier than what was clinically performed is one of the most frequently cited findings in toxicology payment integrity audits.

Definitive Drug Testing by Drug Class --- Commercial & Medicaid

CPT 80320--80377, 83992

Non-Medicare definitive testing reported per drug class or category rather than by tier, including alcohol biomarkers (80320-80321), amphetamines (80324-80326), benzodiazepines (80346), buprenorphine (80348), fentanyl (80354), and opioids and opiate analogs (80361-80365).

Key Billing Consideration

Each drug class is billed once per date of service no matter how many individual drugs within that class were identified --- commercial payers routinely reject claims that itemize every analyte within a single class separately.

Alcohol & Alcohol Biomarker Testing

CPT 80320--80321, 82075

Ethanol screening (80320), ethyl glucuronide and ethyl sulfate biomarker testing for extended abstinence monitoring (80321), and breath alcohol testing (82075) used across SUD monitoring, legal, and DOT-regulated testing contexts.

Key Billing Consideration

Ethyl glucuronide and ethyl sulfate testing is frequently denied for medical necessity when ordered as routine surveillance without a documented abstinence-monitoring treatment plan tied to the order.

Pain Management & Chronic Opioid Therapy Monitoring

Baseline and periodic presumptive screening at scheduled visits, definitive confirmation testing triggered by unexpected results or adherence concerns, and monitoring panels aligned to each patient's specific prescribed medication regimen under chronic opioid therapy.

Key Billing Consideration

Medicare and most commercial LCDs require a documented risk assessment and a stated clinical reason for escalating to definitive testing --- claims missing that link are among the most commonly denied in pain management toxicology.

Substance Use Disorder (SUD) & Medication-Assisted Treatment (MAT) Testing

Admission baseline panels, ongoing adherence monitoring for buprenorphine, methadone, and naltrexone, and unexpected-result confirmation testing across residential, outpatient, and office-based MAT settings.

Key Billing Consideration

Many state Medicaid programs and commercial payers cap definitive testing frequency for SUD treatment patients --- billing beyond those caps without a documented change in clinical status is a leading denial driver in behavioral health toxicology.

Workplace, Forensic & DOT-Regulated Testing

Federally mandated DOT and non-DOT workplace drug testing panels, chain-of-custody specimen handling and documentation, and forensic toxicology testing performed for legal or regulatory proceedings.

Key Billing Consideration

DOT-regulated and forensic specimens require unbroken chain-of-custody documentation attached to every claim --- a missing custody form is grounds for both payment denial and disqualification of the result in a legal proceeding.

Specimen Validity Testing & Bundled Services

pH, creatinine, specific gravity, and oxidant or adulterant testing performed to confirm a urine specimen's authenticity and integrity before any drug testing result is reported.

Key Billing Consideration

CMS and most commercial payers bundle specimen validity testing into the presumptive or definitive drug testing code --- billing it separately under codes like 81007 or 83986 is a routine, easily detected overbilling pattern that draws payer attention fast.

Our Laboratory RCM Services

TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.

Proficient Across Multiple LIS & EHRs to Simplify Your
Laboratory Management

ChartLogic
Collaborate md
Greenway health
Haemonetics
jane
cgm Labdaq
Modmed
open emr
Harris Data Integrity Solutions
siemens healthineers
Tebra
Oracle Health
Confience
Power path
Benchmark solutions
Xifin
Psyche Systems
veradigm
Turemed Lis
Telcor
Practice pro
novo path
Nextgen Healthcare
Next tech
meditech
Advanced data systems corporation
Logilab
Labware
Lab vantage
labs os
Epic
Dr Chrono
dendi
Corepoint
clinisys
Care Cloud
apex healthware
clinisys copathplus
Advanced md
softlab
athenaone

Serving Labs Across The United States

TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.

Medicare Part B Compliance for Toxicology and Drug Testing Laboratories

Toxicology billing under Medicare Part B carries a compliance burden that catches many labs off guard, and one that generalist billing companies rarely have the expertise to manage. The combination of MAC-specific LCDs, tiered definitive testing rules, frequency limitations, and documented medical necessity requirements creates a regulatory environment that demands dedicated, proactive management, especially in pain management and SUD treatment settings where testing volume is highest.
Get in Touch
Local Coverage Determinations (LCDs) for Drug Testing

Each Medicare Administrative Contractor maintains its own LCD governing presumptive and definitive urine drug testing, specifying covered ICD-10 diagnoses, documentation expectations, and utilization controls. These policies differ by MAC and change without notice. TransLabs maintains live LCD databases and validates diagnosis-to-test linkage on every Medicare claim before submission.

Medical Necessity Documentation for Definitive Testing

Medicare requires the medical record to clearly state why definitive confirmation testing was necessary, an unexpected presumptive result, an adherence concern, or a safety risk, not simply that a screen was performed. TransLabs builds documentation prompts into your ordering workflow so the clinical rationale is captured before the claim is ever submitted.

Frequency Limitations & Utilization Management

Medicare and most commercial payers cap how often presumptive and definitive testing can be billed for the same beneficiary within a defined period, often tied to a documented risk stratification score. TransLabs monitors each patient's testing history against these limits and flags orders before they exceed what a payer will cover.

Advance Beneficiary Notices for Non-Covered Definitive Testing

When a definitive testing tier or drug class panel may not meet medical necessity criteria under the applicable LCD, a valid ABN must be issued before the specimen is collected. TransLabs implements ABN workflows into front-end intake specifically for pain management and SUD treatment settings where this risk is highest.

Clinical Laboratory Fee Schedule (CLFS)

The CLFS sets Medicare payment rates for presumptive and definitive drug testing codes and updates annually on January 1. TransLabs monitors CLFS changes, updates billing tables immediately at each rate change, and identifies when a payer is paying below CLFS rates.

PAMA Reporting Requirements

Laboratories meeting the applicable laboratory definition under the Protecting Access to Medicare Act carry mandatory private payer data reporting obligations for drug testing codes during designated collection periods. TransLabs tracks your PAMA obligations and ensures accurate, on-time reporting.

OIG Work Plan Monitoring

The Office of Inspector General's annual Work Plan has repeatedly flagged high-tier definitive drug testing and pain management/SUD-related billing patterns for active audit scrutiny. TransLabs builds compliance protocols specifically around current OIG focus areas to reduce your audit exposure before it becomes a problem.

We Bill Only for Laboratories and That Difference Shows in Every Metric We Track

Most billing companies treat toxicology labs like any outpatient client. They’re not. Toxicology billing has its own tiered coding, documentation standards, frequency/utilization rules, and payer scrutiny in pain management and SUD settings. TransLabs’ team works only in drug testing; no divided attention, no generalist assumptions.

Toxicology & Drug Testing-Exclusive Specialization

Toxicology only; tiered G-codes, drug class coding, not a different specialty last month and definitive panels this month.

98% First-Pass Clean Claims Rate

98%+ clean claims rate across all lab clients with fewer denials, faster payments, stronger cash flow.

Tier & Medical Necessity Documentation Expertise

We build documentation prompts that tie each tier to a clear clinical rationale; labs switching to us see documentation denials drop sharply within 60 days.

High-Volume Architecture

Built for labs processing thousands of daily claims; scalability without sacrificing accuracy.

No Long-Term Contracts

Month-to-month, results-based partnership with measurable improvement in 90 days, no exit fees, just 30 days’ notice.

Transparent Reporting

Monthly dashboards with full visibility of clean claims rate, denial trends, A/R aging, and root cause analysis, no surprises.

Get Your Toxicology Lab's Custom Revenue Recovery Plan

Schedule a call with our toxicology billing specialist. We’ll review your definitive testing tier accuracy, medical necessity documentation, frequency compliance, and A/R days.

What Our Clients Say?

Linda Hutchinson
Linda Hutchinson
Laboratory Director
Our NGS panel denials dropped from 32% to under 6% within three months. TransLabs' expertise with molecular tier codes, prior authorization management, and LCD compliance has been invaluable. They understand the nuances of genetic testing billing that our previous vendor completely missed.
Peter Wozniak
Peter Wozniak
Pathologist & Laboratory Owner
We've worked with three other billing companies over the years. TransLabs is the only one that truly understands complex surgical pathology coding, immunohistochemistry billing, and the nuances of TC/PC modifiers. Clean claims rate improved to 99%, and our dermatopathology reimbursement increased 27%.
James Patton
James Patton
Cytogenetics Laboratory Manager
Before TransLabs, our FISH and karyotype claims were a constant struggle with denials and underpayments. Their coders actually understand probe configurations, complexity levels, and when to use 88271 versus 88275. Our cytogenetics revenue increased 34% in the first year.

Book Consultation Today!

Stop Leaving Reimbursements on the Table

Join 500+ diagnostic and clinical laboratories, pain management clinics, and SUD treatment programs that trust TransLabs, the laboratory billing company built for growth. Start with our complimentary claims audit. Our toxicology billing specialists will review your presumptive and definitive coding, your tier selection accuracy, and your denial trends to show you exactly what’s recoverable.

Dedicated billing specialist assigned to your lab or clinic

Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers

Uncover your top 3 revenue leaks (tier miscoding, documentation gaps, frequency violations)

Custom strategy tailored to your test menu and EHR/LIS software

Live in 24 hours with no contracts and no upfront fees

Pay only a percentage of what we collect for you

Frequently Asked Questions

What is the difference between presumptive and definitive drug testing billing?

Presumptive testing (CPT 80305-80307) is qualitative screening that determines whether a drug or drug class is present, billed once per patient per day regardless of how many classes were screened. Definitive testing (HCPCS G0480-G0483, G0659, or CPT 80320-80377 for non-Medicare payers) identifies specific drugs and metabolites by GC/MS or LC/MS and generally requires a documented clinical trigger beyond the presumptive result.
Medicare’s tiered structure bills based strictly on the number of drug classes tested: G0480 for 1-7 classes, G0481 for 8-14, G0482 for 15-21, and G0483 for 22 or more. The tier billed must match exactly what was ordered, performed, and documented; billing a higher tier than the chart supports is one of the most common toxicology audit findings.
Typically 6-9% of net collections, reflecting the documentation and utilization management complexity specific to drug testing. TransLabs charges transparently with no setup fees, tech fees, or long-term contracts. Revenue gains from accurate tier selection and reduced denials usually offset the fee within 30-60 days.
The medical record must state the specific clinical reason definitive testing was necessary, such as an unexpected presumptive result, a medication adherence concern, or a diversion or safety risk, along with the treating provider’s order. TransLabs builds these documentation prompts directly into your ordering workflow.
Yes. Our coders handle the full range of toxicology billing settings, including chronic opioid therapy monitoring, medication-assisted treatment adherence testing, alcohol biomarker panels, and workplace or forensic testing with chain-of-custody requirements.
Industry benchmark for toxicology labs runs 10-15%, higher than routine clinical labs due to medical necessity and frequency scrutiny. TransLabs clients typically operate below 5%. Common denial drivers include tier miscoding, missing definitive testing documentation, and frequency limit violations.
Yes, we’ve integrated with laboratory information systems and EHR platforms commonly used in pain management and SUD treatment settings, including automated charge capture, tier calculation, and frequency tracking, typically completed within two weeks.
Most labs and clinics see results within 60-90 days: onboarding and credentialing in the first 30 days, tier and documentation-related denial improvement by day 60, and by day 90, a documented clean claims rate above 95% with measurable revenue growth in a performance report.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!